Snake venoms are complex protein mixtures with different biological activities that can act in both their preys and human victims. Many of these proteins play a role in prey capture and in the digestive process of these animals.
It is known that some snakes are resistant to the toxicity of their own venom by mechanisms not yet fully elucidated. However, it was observed in the Laboratory of Herpetology of Instituto Butantan that some Bothrops moojeni individuals injured by the same snake species showed mortalities caused by envenoming effects. This study analyzed the biochemical composition of 13 venom and plasma samples from Bothrops moojeni specimens to assess differences in their protein composition.
Application of sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) showed distinct venom protein profiles, but very homogeneous plasma profiles. Western Blotting (WB) was performed with plasma samples, which were submitted to incubation with the respective venom.
Some individuals showed an immunorecognized band zone around 25 kDa, indicating interaction between the same individual plasma and venom proteins. Crossed-WB assay using non-self-plasma and venom showed that this variability is due to venom protein composition instead of plasma composition.
These venoms presented higher caseinolytic, collagenolytic and coagulant activities than the venoms without these regions recognized by WB. Mass spectrometry analyses performed on two individuals revealed that these individuals present, in addition to higher protein concentrations, other exclusive proteins in their composition. When these same two samples were tested in vivo, the results also showed higher lethality in these venoms, but lower hemorrhagic activity than in the venoms without these regions recognized by WB.
5-FOA, 25g |
R7039-25g |
ACTGene |
|
EUR 963 |
Chlortetracycline HCl EP |
C029-25G |
TOKU-E |
25 g |
EUR 141 |
DiagPoly Protein A Conjugated Polystyrene Particles, 3.0-3.9 µm |
DNM-C029 |
Creative Diagnostics |
5 mL |
EUR 767 |
Chlortetracycline HCl EP |
C029-100G |
TOKU-E |
100 g |
EUR 321 |
Chlortetracycline HCl EP |
C029-5G |
TOKU-E |
5 g |
EUR 65 |
Recombinant Human Epidermal Growth Factor/EGF |
C029-10ug |
Novoprotein |
10ug |
EUR 70 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, pH 7.0. |
Recombinant Human Epidermal Growth Factor/EGF |
C029-1mg |
Novoprotein |
1mg |
EUR 192 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, pH 7.0. |
Recombinant Human Epidermal Growth Factor/EGF |
C029-500ug |
Novoprotein |
500ug |
EUR 149 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, pH 7.0. |
Recombinant Human Epidermal Growth Factor/EGF |
C029-50ug |
Novoprotein |
50ug |
EUR 100 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 200mM NaCl, pH 7.0. |
Quinine Sulfate |
Q012-25G |
TOKU-E |
25g |
EUR 64 |
Sarafloxacin Hydrochloride |
S003-25G |
TOKU-E |
25 g |
EUR 168 |
Spectinomycin dihydrochloride pentahydrate |
S006-25G |
TOKU-E |
25 g |
EUR 258 |
Streptomycin Sulfate |
S008-25G |
TOKU-E |
25 g |
EUR 48 |
Sulfadiazine |
S012-25G |
TOKU-E |
25 g |
EUR 62 |
Sodium Pyruvate |
S024-25G |
TOKU-E |
25 g |
EUR 63 |
Sulfamethazine |
S026-25G |
TOKU-E |
25 g |
EUR 58 |
Sulfadoxine (Sulphadoxine) |
S035-25G |
TOKU-E |
25 g |
EUR 163 |
Streptomycin Sulfate EP |
S040-25G |
TOKU-E |
25 g |
EUR 48 |
Salicin |
S060-25G |
TOKU-E |
25g |
EUR 138 |
Sulfapyridine USP |
S065-25G |
TOKU-E |
25 g |
EUR 85 |
Menadione |
M079-25G |
TOKU-E |
25 g |
EUR 54 |
Menadione sodium bisulfite |
M080-25G |
TOKU-E |
25 g |
EUR 64 |
Mebendazole |
M082-25G |
TOKU-E |
25 g |
EUR 76 |
N-Methylhydroxylamine hydrochloride |
M088-25G |
TOKU-E |
25 g |
EUR 162 |
Neomycin Sulfate USP |
N003-25G |
TOKU-E |
25 g |
EUR 72 |
Nalidixic Acid |
N011-25G |
TOKU-E |
25 g |
EUR 77 |
Neomycin Sulfate EP |
N012-25G |
TOKU-E |
25 g |
EUR 72 |
Nisin |
N013-25G |
TOKU-E |
25 g |
EUR 443 |
α-Naphthaleneacetic acid (1-NAA) |
N024-25G |
TOKU-E |
25 g |
EUR 51 |
2-Naphthoxyacetic acid (BNOA) |
N025-25G |
TOKU-E |
25 g |
EUR 49 |
Nisin Z |
N055-25G |
TOKU-E |
25 g |
EUR 486 |
Oxolinic acid |
O002-25G |
TOKU-E |
25 g |
EUR 335 |
Lactobionic acid |
L017-25G |
TOKU-E |
25 g |
EUR 99 |
Metronidazole |
M011-25G |
TOKU-E |
25 g |
EUR 109 |
Paromomycin sulfate |
P002-25G |
TOKU-E |
25 g |
EUR 499 |
Praziquantel |
P011-25G |
TOKU-E |
25 g |
EUR 161 |
Pyrazinamide |
P020-25G |
TOKU-E |
25 g |
EUR 84 |
Penicillin V potassium |
P027-25G |
TOKU-E |
25 g |
EUR 86 |
Picloram |
P043-25G |
TOKU-E |
25 g |
EUR 345 |
110-Phenanthroline hydrochloride monohydrate |
P067-25G |
TOKU-E |
25 g |
EUR 185 |
Putrescine Dihydrochloride |
P103-25G |
TOKU-E |
25 g |
EUR 56 |
Pyrazinecarboxamide |
P128-25G |
TOKU-E |
25g |
EUR 83 |
2-Oxazolidone |
O038-25G |
TOKU-E |
25g |
EUR 66 |
Furazolidone |
F004-25G |
TOKU-E |
25 g |
EUR 114 |
Fosfomycin Sodium |
F013-25G |
TOKU-E |
25 g |
EUR 235 |
Folic acid USP |
F014-25G |
TOKU-E |
25 g |
EUR 124 |
Flurbiprofen |
F036-25G |
TOKU-E |
25 g |
EUR 889 |
Flurbiprofen Sodium |
F037-25G |
TOKU-E |
25 g |
EUR 889 |
Flubendazole |
F040-25G |
TOKU-E |
25 g |
EUR 215 |
8-Hydroxyquinoline |
H006-25G |
TOKU-E |
25 g |
EUR 65 |
Hydroxyurea |
H035-25G |
TOKU-E |
25 g |
EUR 250 |
Hexadecylpyridinium bromide |
H036-25G |
TOKU-E |
25 g |
EUR 63 |
G418 Disulfate |
G001-25G |
TOKU-E |
25 g |
EUR 322 |
Gentamicin Sulfate USP |
G006-25G |
TOKU-E |
25 g |
EUR 392 |
Gentamicin Sulfate EP |
G007-25G |
TOKU-E |
25 g |
EUR 399 |
Griseofulvin |
G008-25G |
TOKU-E |
25 g |
EUR 173 |
G418 Disulfate (Low Endotoxin) |
G048-25G |
TOKU-E |
25 g |
EUR 411 |
Rifampicin |
R003-25G |
TOKU-E |
25 g |
EUR 572 |
Riboflavin |
R009-25G |
TOKU-E |
25 g |
EUR 55 |
Irgasan (Triclosan) |
I002-25G |
TOKU-E |
25 g |
EUR 118 |
Indole-3-acetic acid |
I014-25G |
TOKU-E |
25 g |
EUR 87 |
Indole-3-butyric acid |
I015-25G |
TOKU-E |
25 g |
EUR 123 |
Indole-3-carbinol |
I034-25G |
TOKU-E |
25 g |
EUR 199 |
Indomethacin |
I037-25G |
TOKU-E |
25 g |
EUR 115 |
Kanamycin Acid Sulfate BP |
K004-25G |
TOKU-E |
25 g |
EUR 251 |
Kanamycin Sulfate USP |
K008-25G |
TOKU-E |
25 g |
EUR 164 |
Kanamycin Acid Sulfate for BioProcessing |
K012-25G |
TOKU-E |
25 g |
EUR 379 |
Kanamycin Acid Sulfate EW |
K029-25G |
TOKU-E |
25 g |
EUR 248 |
Econazole nitrate |
E001-25G |
TOKU-E |
25 g |
EUR 208 |
Erythromycin |
E002-25G |
TOKU-E |
25 g |
EUR 209 |
Erythromycin Ethylsuccinate |
E004-25G |
TOKU-E |
25 g |
EUR 203 |
In conclusion, some Bothrops moojeni specimens differ in venom composition, which may have implications in envenomation. Moreover, the high individual venom variability found in this species demonstrates the importance to work with individual analyses in studies involving intraspecific venom variability and venom evolution.